Table 3.
Complete Response n (%) |
Phase | Sequence | Panel 1 | Panel 2 |
Acute | AB | 5 (15) | 0 | |
BA | 1 (3) | 6 (17) | ||
Delay | AB | 9 (27) | 1 (3) | |
BA | 0 | 8 (23) |
Sequence AB: Intervention by Persumac before crossover and then Placebo after crossover; Sequence BA: Intervention by Placebo before crossover and then Persumac after crossover, Panel 1: Intervention before crossover; Panel 2: Intervention after crossover.